DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for androgenetic alopecia — screening already-approved drugs against its 30-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAndrogenetic alopecia maps to a 30-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for androgenetic alopecia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tryptophanyl tRNA synthetase 2, mitochondrial (WARS2) — WARS2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 5sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5EKD · 1.82 Å · ligand (5S)-5-[(1R)-1-(1H-indol-3-yl)ethyl]-2-(methylamino)-1,3-oxazol-4(5H)-one (5BX). Experimental structure, not a prediction.
What the evidence adds up to
A 2000 classification system for androgenetic alopecia was developed to quantify parameters such as hair density, caliber, shape, length, growth rate, and colour, and the authors reported that it proved efficient during the fluctuations of different parameters in hormonal and minoxidil treatments. A 2022 narrative review states that the main focus of medical treatment options with significant evidence as of now includes minoxidil, 5 alfa-reductase inhibitors, low light laser therapy, and platelet-rich plasma. The same review notes that few medications are FDA-approved for the condition and that dermatologists are often reluctant to try off-label therapies.
A 2022 clinical case describes a 34-year-old man with a disease duration of more than ten years who was treated without finasteride and with a lower dosage of minoxidil. The combined treatment program, which included hair growth stimulation, blocking the action of androgens on the scalp, and a course of injections, was reported to significantly improve results due to the growth of new hair, an increase in the total number of hair, and hair in the anagen stage. This is a single case, not a controlled trial.
No abstract provides a controlled trial showing a specific drug repurposed for androgenetic alopecia with concrete survival or response rates. The evidence base remains limited to established treatments and small case reports. What is still missing are large, randomised, placebo-controlled trials that test candidate drugs in well-defined patient subgroups, adequate funding for such trials, and a standardised outcome measure that goes beyond subjective or single-centre assessments.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Dermatologic Surgery · 2000 · 46 citations
Multifactorial Classification of Male and Female Androgenetic Alopecia
AbstractBACKGROUND: Various classifications of male androgenetic alopecia have been described. In fact, all the classification schemes proposed so far are only topographic. A more objective, accurate, and detailed approach to classifying baldness is needed. OBJECTIVE: To propose a dynamic multifactorial classification of certain parameters that can be quantitated and computerized. METHODS: A multifactorial classification has been developed to study parameters such as fixed distances of the face, scalp mobility and thickness, and covering power of hair. This includes density, caliber, shape, length, growth rate, and hair color. RESULTS: Classification proved to be efficient during the fluctuations of different parameters in hormonal and minoxidil treatments. It also helps to determine surgical indications of hair transplant and the stage of maximal baldness. CONCLUSION: This approach will lead to a better evaluation of the evolution of androgenetic alopecia in both sexes, either spontaneously or under treatment.
JEADV Clinical Practice · 2022 · 23 citations · open access
The state‐of‐the‐art in the management of androgenetic alopecia: A review of new therapies and treatment algorithms
AbstractAbstract Androgenetic alopecia is one of the most common dermatologic disorders in the daily clinical practice of dermatologists. Despite it is such a common entity, few medications are FDA‐approved for its treatment. Due to this situation dermatologists are often reluctant to try off‐label therapies. This guide's purpose is to review the current available therapies for androgenetic alopecia including those off‐label, and to propose treatment algorithms according to the published scientific research.
AbstractThere are a number of options available for the medical management of androgenetic alopecia. The key questions for practitioners are what the available medications are and what is their efficacy? What are the possible side-effects of these options? Are there differences in response according to parameters like gender? Are combinations effective? What are the newer options available and what could the future hold? This narrative review attempts to answer these questions. The main focus is on the medical treatment options which have significant evidence as of now – minoxidil, 5 alfa-reductase inhibitors, low light laser therapy, and platelet-rich plasma.
COMPLEX APPROACH TO THE TREATMENT OF ANDROGENETIC ALOPECIA IN MALE PERSONS WITH A POOR PROGNOSIS OF THE DISEASE
AbstractWe have described a clinical case of successful treatment of androgenetic alopecia without the use of finasteride and with the use of minoxidil at a lower dosage in a 34-year-old man. with a disease duration of more than 10 years, who applied on an outpatient basis. The combined treatment program (a combination of hair growth stimulation and blocking the action of androgens on the scalp and a course of injections) made it possible to significantly improve the results of treatment due to the growth of new hair, an increase in the total number of hair and hair in the anagen stage. The described clinical case illustrates the need for a comprehensive approach to the treatment of androgenetic alopecia in patients with severe course and poor prognosis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
